Neurotech Reports Positive Top-Line Phase I/II Rett Syndrome Clinical Trial Results Key Points:
• NTIRTT1 is the first clinical trial to show a statistically significant clinical improvement in Rett Syndrome patients (n=14) with a broad-spectrum cannabinoid drug therapy (NTI164)
• Primary endpoint of Clinical Global Impression – Improvement (CGI-I) at 12 weeks versus baseline was met; mean improvement of -0.3, (p=0.04)
• CGI-I compares favourably to the only FDA approved Rett Syndrome drug DAYBUE™ (trofinetide) Phase 3 CGI-I data vs placebo in Rett -0.3, 8% improvement (p=0.003)
https://www.investi.com.au/api/announcements/nti/6b645e01-525.pdf
Neurotech Reports Positive Top-Line Phase I/II Rett Syndrome...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $79.35M | |||
| Open | High | Low | Value | Volume |
| 7.8¢ | 8.0¢ | 7.7¢ | $173.4K | 2.194M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 316074 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 84444 | 1 |
View Market Depth
| Last trade - 15.59pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.9¢ |
Change
0.000 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.8¢ | 8.0¢ | 7.7¢ | 463708 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| NTI (ASX) Chart |